

ASX Announcement

10 June 2026

TRIPP-FFX Abstract Accepted as Rapid Oral Presentation at ESMO GI 2026

Sydney, Australia – 10 June 2026: OncoSil Medical Limited (ASX:OSL) ("OncoSil Medical" or "the Company"), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce that the TRIPP-FFX study abstract has been selected for a **Rapid Oral Presentation** at the prestigious European Society for Medical Oncology Gastrointestinal Cancers Congress 2026 (ESMO GI 2026), one of the world's leading scientific meetings focused on gastrointestinal cancers.

The selection of TRIPP-FFX for oral presentation highlights the growing international interest in the clinical potential of the OncoSil™ device and follows the Company's recent announcement that the study achieved its co-primary endpoints (ASX announcement dated 9 June 2026).

ESMO GI 2026 will take place in Munich, Germany from 1 - 4 July 2026 and is recognised as one of the leading international scientific congresses dedicated to gastrointestinal cancers.

The accepted abstract is titled:

TRIPP-FFX: An open-label, multi-centre, randomized study of TaRgeted Intratumoural Placement of Phosphorous-32 microparticles added to FOLFIRINOX (FFX) versus FFX alone in patients with unresectable locally advanced pancreatic cancer (LAPC).

The presentation will include findings from the TRIPP-FFX study, which evaluated the safety and efficacy of the OncoSil™ device in addition to FOLFIRINOX chemotherapy in patients with unresectable LAPC.

The Rapid Oral Presentation is scheduled for **4 July 2026 at 08:30 CEST (4.30pm AEST)**, providing a high-profile platform for the Company to present its data to an international audience of leading gastrointestinal cancer specialists and key opinion leaders.

Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

"The selection of TRIPP-FFX as a Rapid Oral Presentation at ESMO GI 2026 is an important milestone for OncoSil Medical and a strong endorsement of the scientific significance of our study.

Following the achievement of the study's co-primary endpoints, we are excited to present the TRIPP-FFX findings to one of the most influential audiences in gastrointestinal oncology. The opportunity to showcase our data at ESMO GI further elevates awareness of OncoSil™ among leading clinicians, researchers and potential strategic stakeholders globally.

We believe this presentation represents another important step in building the clinical evidence base supporting OncoSil™ and advancing our regulatory and commercial objectives in key markets."

The significance of this selection is underscored by the scale and competitiveness of the ESMO Gastrointestinal Cancers Congress. At the 2025 meeting, ESMO GI attracted 3,792 participants from 103 countries and territories, with 453 scientific abstracts presented. Of these, only 4 were selected as late-breaking abstracts.

The inclusion of the TRIPP-FFX study as a Rapid Oral Presentation at ESMO GI 2026 places OncoSil Medical's clinical data among a highly selective group of studies chosen for presentation to one of the largest and most influential audiences in gastrointestinal oncology.

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 160 96424981	Mr. Tim Luscombe & Ms. Nova Taylor Joint Company Secretaries E: tim.luscombe@bio101.com & nova.taylor@bio101.com T: +61 429 707 079 & +61 414 877 703
---	--

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year¹. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Australia, Türkiye and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

1. <https://gco.iarc.fr/en>